Home > HCP

8 Variable Kidney Failure Risk Estimator.

As you know the progression of kidney disease is dependent on multiple factors. A kidney failure risk equation was developed by using meta-analysis of data from patients with CKD stages 3-5 referred to nephrologists in Canada, which has now been validated in more than 700,000 individuals spanning 30 + countries worldwide.

An estimator was developed using the equation. The estimator takes into account the 8 individual variables of gender, age, eGFR, UACR, serum calcium, serum phosphorus, serum bicarbonate and serum albumin.

Users may be impressed by the calculated benefit of improved serum bicarbonate. Achieving optimal serum bicarbonate levels with Bicarbi may be a low cost, well tolerated manner in which to slow the progression of kidney function decline.

Nephcentric has had no influence in the development of the equation, nor does nephcentric make any claims on the accuracy of the estimator.

If you would like to access kidney failure risk estimator based off of the 8 variable equation or if you would like to access the clinical data from which the estimator was derived, please click the appropriate button below.

Click here for the supporting clinical data

Click here to access the estimator

Starting or converting patients to Bicarbi.

Clinical experience with Bicarbi indicates increased efficacy as compared to uncoated sodium bicarbonate tablets with a dramatically improved GI side effect profile. Based upon reports from clinicians, it generally appears that Bicarbi has 1.3 to 1.4 times the potency of raw uncoated sodium bicarbonate mg per mg. This said we frequently receive reports of Bicarbi having efficacy 2 times that of raw sodium bicarbonate. When switching a patient you may try 2 Bicarbi capsules for every 3 650 mg sodium bicarbonate tablets. For patients who are being newly started, a dose of 2 capsules per day is suggested, which can be adjusted as needed to achieve a serum bicarbonate of 23-29 mEq/l or as desired.

Patient and HCP feedback on Bicarbi

We solicit feedback from patients and HCPs about their experience with Bicarbi. We also track refill rates. Nationally, adherence rates for PO medications range between 37-72% depending on disease state, cost of therapy, and side effects. Our data indicate that the refill rates for bicarbi are above 80%. Patients taking Bicarbi tell us "It's like taking bicarb, but without the bloat and burp". Published Clinical data indicate the most common reason for intolerance or non-adherance to alkali therapy with sodium bicarbonate is due to GI side effects like bloating. (See Clinical References).

Dispense Bicarbi from your clinic

If you are interested in purchasing Bicarbi wholesale so it can be dispensed to patients from your clinic, please contact us at sales@nephcentric.com